Article in ACS chemical biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
5 citing papers in PubMed, 7 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors at 2 institutions in 2 countries.
Jin GanDepartment of Cell and Chemical Biology, Division of Chemical Biology and Drug Discovery, Leiden University Medical Center, Einthovenweg 20, 2333 ZC Leiden, The Netherlands.ORCID 0000-0002-8785-3035
Jelle de VriesDepartment of Cell and Chemical Biology, Division of Chemical Biology and Drug Discovery, Leiden University Medical Center, Einthovenweg 20, 2333 ZC Leiden, The Netherlands.
Jimmy J L L AkkermansDepartment of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center LUMC, Einthovenweg 20, 2333 ZC Leiden, The Netherlands.ORCID 0000-0002-8000-7952
Yassene MohammedCenter for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZC Leiden, The Netherlands.ORCID 0000-0003-3265-3332
Rayman T N TjokrodirijoCenter for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZC Leiden, The Netherlands.
Arnoud H de RuCenter for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZC Leiden, The Netherlands.
Robbert Q KimDepartment of Cell and Chemical Biology, Division of Chemical Biology and Drug Discovery, Leiden University Medical Center, Einthovenweg 20, 2333 ZC Leiden, The Netherlands.ORCID 0000-0003-1834-8673
David A VargasDepartment of Chemistry, University of Rochester, Hutchison Hall, 120 Trustee Rd, Rochester, New York 14627, United States.
Vito PolDepartment of Cell and Chemical Biology, Division of Chemical Biology and Drug Discovery, Leiden University Medical Center, Einthovenweg 20, 2333 ZC Leiden, The Netherlands.
Rudi FasanDepartment of Chemistry, University of Rochester, Hutchison Hall, 120 Trustee Rd, Rochester, New York 14627, United States.ORCID 0000-0003-4636-9578
Peter A van VeelenCenter for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZC Leiden, The Netherlands.ORCID 0000-0002-7898-9408
Jacques NeefjesDepartment of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center LUMC, Einthovenweg 20, 2333 ZC Leiden, The Netherlands.
Hans van DamDepartment of Cell and Chemical Biology, Division of Chemical Biology and Drug Discovery, Leiden University Medical Center, Einthovenweg 20, 2333 ZC Leiden, The Netherlands.
Huib OvaaDepartment of Cell and Chemical Biology, Division of Chemical Biology and Drug Discovery, Leiden University Medical Center, Einthovenweg 20, 2333 ZC Leiden, The Netherlands.ORCID 0000-0002-0068-054X
Aysegul SapmazDepartment of Cell and Chemical Biology, Division of Chemical Biology and Drug Discovery, Leiden University Medical Center, Einthovenweg 20, 2333 ZC Leiden, The Netherlands.ORCID 0000-0003-3942-7602
Paul P GeurinkDepartment of Cell and Chemical Biology, Division of Chemical Biology and Drug Discovery, Leiden University Medical Center, Einthovenweg 20, 2333 ZC Leiden, The Netherlands.ORCID 0000-0003-1849-1111
Leiden University Medical Center · NLUniversity of Rochester · US
Funding
Selective P450 Oxidation Catalysts for Synthesis of Bioactive MoleculesR01GM098628 · NIGMS · UNIVERSITY OF TEXAS DALLAS · PI FASAN, RUDI · 2012 to 2024
$4.7M
Matrix-Assisted Laser Desorption Ionization Time-of-Flight (MALDI-TOF/TOF) Mass SpectrometerS10OD030302 · OD · UNIVERSITY OF ROCHESTER · PI NILSSON, BRADLEY L. · 2021 to 2021
$304k
NIGMS NIH HHS R01 GM098628NIH HHS S10 OD030302
6 · The paper itself
Abstract
Ubiquitin thioesterase OTUB2, a cysteine protease from the ovarian tumor (OTU) deubiquitinase superfamily, is often overexpressed during tumor progression and metastasis. Development of OTUB2 inhibitors is therefore believed to be therapeutically important, yet potent and selective small-molecule inhibitors targeting OTUB2 are scarce. Here, we describe the development of an improved OTUB2 inhibitor,
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Cellular Validation of a Chemically Improved Inhibitor Identifies Monoubiquitination on OTUB2. · full record | OpenQuestion